Embed

Academic

Authors

Chiara Tommasi

Chiara Tommasi,Service de pédiatrie,Diseases,Virology,Immunology

Edit

Chiara Tommasi

Service de pédiatrie

Publications: 16 | Citations: 15

Fields: Diseases, Virology, Immunology

Collaborated with 82 co-authors from 2008 to 2011 | Cited by 109 authors

Cumulative Annual

Sort by:

Publications (16)

BibTeX | RIS | RefWorks Download

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

, , , , , , , ,

Journal: Malaria Journal - MALAR J , vol. 10, no. 1, pp. 1-3, 2011

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir With and Without Maraviroc Coadministration (Citations: 4)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=33615726&selfId1=37452915&selfId2=0&maxNumber=12&query=

Journal: Annals of Pharmacotherapy - ANN PHARMACOTHER , vol. 44, no. 5, pp. 838-843, 2010

Comparison of real-time PCR methods for measurement of HIV1 proviral DNA (Citations: 2)

, , , , , , ,

Journal: Journal of Virological Methods - J VIROL METH , vol. 164, no. 1, pp. 135-138, 2010

A rare case of severe myopathy associated with etravirine use (Citations: 1)

, , , , , ,

Journal: Aids , vol. 24, no. 7, pp. 1088-1090, 2010

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=37686859&selfId1=37452915&selfId2=0&maxNumber=12&query=

Journal: Jaids-journal of Acquired Immune Deficiency Syndromes - JAIDS , 2010

Sort by:

Citations (15 times by 15 publications)

Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients

, , , , , , , ,

Journal: Journal of Clinical Pharmacology - J CLIN PHARMACOL , vol. 52, no. 3, pp. 440-445, 2012

Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)

, , , , , , , , ,

Journal: Journal of The International Association of Physicians in Aids Care (jiapac) , vol. 11, no. 3, pp. 192-197, 2012

IDENTIFICATION AND CHARACTERIZATION OF DEGRADATION PRODUCTS OF RALTEGRAVIR USING LC, LC–MS/TOF AND MS

, ,

Journal: Journal of Liquid Chromatography & Related Technologies - J LIQ CHROMATOGR RELAT TECHNO , vol. just-accep, no. just-accep, 2012

Selected amino acid mutations in HIV1 B subtype gp41 are Associated with Specific gp120 V3 signatures in the regulation of Co-Receptor usage (Citations: 1)

, , , , ,

Journal: Retrovirology , vol. 8, no. 1, pp. 1-11, 2011

Cellular HIV1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=48049313&selfId1=37452915&selfId2=0&maxNumber=12&query=

Journal: BMC Infectious Diseases - BMC INFECT DIS , vol. 11, no. 1, pp. 1-9, 2011

Comments

Co-authors (82)

Journals (14)

Keywords (36)

Chiara Tommasi,Service de pédiatrie,Diseases,Virology,Immunology

Publications (16)

BibTeX | RIS | RefWorks Download

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir With and Without Maraviroc Coadministration (Citations: 4)

Comparison of real-time PCR methods for measurement of HIV1 proviral DNA (Citations: 2)

A rare case of severe myopathy associated with etravirine use (Citations: 1)

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens

Citations (15 times by 15 publications)

Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients

Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)

IDENTIFICATION AND CHARACTERIZATION OF DEGRADATION PRODUCTS OF RALTEGRAVIR USING LC, LC–MS/TOF AND MS

Selected amino acid mutations in HIV1 B subtype gp41 are Associated with Specific gp120 V3 signatures in the regulation of Co-Receptor usage (Citations: 1)

Cellular HIV1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration


	View FAQ about top research areas and Fields of study

Chiara Tommasi,Service de pédiatrie,Diseases,Virology,Immunology

Publications (16) BibTeX | RIS | RefWorks Download

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir With and Without Maraviroc Coadministration (Citations: 4)

Comparison of real-time PCR methods for measurement of HIV1 proviral DNA (Citations: 2)

A rare case of severe myopathy associated with etravirine use (Citations: 1)

Selected amino acid mutations in HIV1 B subtype gp41 are Associated with Specific gp120 V3 signatures in the regulation of Co-Receptor usage (Citations: 1)

Publications (16)

BibTeX | RIS | RefWorks Download